Core Insights - Heartflow, Inc. has introduced the Heartflow PCI Navigator, an AI-driven tool designed to enhance percutaneous coronary interventions (PCI) planning by providing interventional cardiologists with a patient-specific 3D model that integrates anatomy, plaque composition, and lesion-specific physiology [1][4][11] - The PLAN CALCIUM study will be presented at the TCT 2025 conference, showcasing how AI-powered plaque analysis can influence decisions in managing highly calcified lesions during PCI [6][2] - The NAVIGATE-PCI registry will enroll approximately 2,500 patients across 30 sites to evaluate the impact of CT-guided PCI planning on physician confidence, procedural safety, and patient outcomes [8][9] Company Overview - Heartflow is a leader in AI technology for coronary artery disease (CAD), with a focus on transforming how clinicians manage care through innovative solutions [11] - The company has a robust data pipeline built from over 110 million annotated CTA images, supporting its AI-driven solutions that have been validated through over 100 studies involving more than 365,000 patients [10][11] - Heartflow's technology is backed by ACC/AHA guidelines and has been proven in real-world practice, achieving coronary CTA image acceptance rates exceeding 96% [10] Product Features - PCI Navigator integrates essential measurements, including IVUS-like and FFR-like visualizations, into a seamless web-based interface, streamlining the decision-making process in the cath lab [3][5] - The tool enhances planning by providing insights into lesion-specific physiology, stent landing zones, and optimal outcomes, thereby improving procedural efficiency and clinical confidence [7][5] Research and Development - The PLAN CALCIUM study demonstrated that AI-powered plaque analysis can significantly alter plans for calcium modification in over half of the lesions evaluated, indicating the potential for more precise coronary interventions [6][8] - The NAVIGATE-PCI registry aims to address unmet needs in PCI planning and is expected to lead to broader clinical use of PCI Navigator by 2026 [9][8]

Core Insights - Heartflow, Inc. has introduced the Heartflow PCI Navigator, an AI-driven tool designed to enhance percutaneous coronary interventions (PCI) planning by providing interventional cardiologists with a patient-specific 3D model that integrates anatomy, plaque composition, and lesion-specific physiology [1][16] - The PLAN CALCIUM study will present data at the TCT 2025 conference, demonstrating how AI-powered plaque analysis can influence decisions in managing highly calcified lesions during PCI [6][2] - The NAVIGATE-PCI registry will enroll approximately 2,500 patients across 30 sites to evaluate the impact of CT-guided PCI planning on physician confidence, procedural safety, and patient outcomes [8][9] Company Overview - Heartflow is a leader in AI technology for coronary artery disease (CAD), with a focus on transforming how clinicians manage care through innovative solutions backed by extensive clinical evidence [10][15] - The company has developed a proprietary data pipeline from over 110 million annotated CTA images, which supports its AI-driven solutions and has been validated in over 100 studies involving more than 365,000 patients [10] - Heartflow's technology is designed to provide actionable insights into plaque location, volume, and composition, facilitating early detection and accurate diagnosis of CAD [15] Product Features - The PCI Navigator integrates essential measurements, including IVUS-like and FFR-like visualizations, into a seamless web-based interface, streamlining the decision-making process in the cath lab [3][5] - The tool enhances planning by allowing interventional cardiologists to review and input data on anatomy, plaque, and lesion-specific physiology before procedures, addressing the information gap that often exists prior to PCI [4][5] - The technology aims to improve efficiency and clinical confidence for both patients and healthcare staff by consolidating necessary information into one intuitive view [5][4] Research and Development - The PLAN CALCIUM study highlights the potential of combining Heartflow Plaque Analysis with coronary CTA imaging and FFRCT analysis, showing that over half of the lesions had altered plans for calcium modification due to AI insights [6][7] - The NAVIGATE-PCI registry is set to begin in 2026, aiming to assess the broader clinical use of PCI Navigator and its impact on interventional practice and patient care [8][9]